Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
P/E ratio for Fusion Antibodies plc (FAB)
P/E ratio as of September 2026 TTM: -6.42
According to Fusion Antibodies plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.42. At the end of 2024 the company had a P/E ratio of -0.96.
P/E ratio history for Fusion Antibodies plc from 2013 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -6.42 86.73%
2025 -3.44 258.24%
2024 -0.96 -75.09%
2023 -3.86 -70.26%
2022 -12.97 -5.91%
2021 -13.79 -54.21%
2020 -30.11 504.68%
2019 -4.98 -79.50%
2018 -24.29 -110.68%
2017 227.44 862.11%
2016 23.64 -107.37%
2015 -320.55 33.40%
2014 -240.30 312.85%
2013 -58.20 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.99 -566.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.30 -665.03%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -18.38 186.17%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.34 263.30%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.